دورية أكاديمية
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
| العنوان: | Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3). |
|---|---|
| المؤلفون: | Donnez J; Department of Gynecology, Université Catholique de Louvain, Brussels, Belgium.; Department of Gynecology, Société de Recherche pour l'Infertilité (SRI), Brussels, Belgium., Becker C; Nuffield Department of Women's & Reproductive Health, Endometriosis CaRe Centre, University of Oxford, Oxford, UK., Taylor H; Department of Obstetrics, Gynecology and Reproductive sciences, Yale School of Medicine, New Haven, CT, USA., Carmona Herrera F; Gynaecology Department, Clinic Institute of Gynaecology, Obstetrics and Neonatology (ICGON), Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain., Donnez O; Département de Gynécologie, Centre de l'Endométriose Complexe, Chirurgie endoscopique pelvienne, Polyclinique Urbain V (ELSAN Group), Avignon, France., Horne A; Department of Gynecology, EXPPECT and MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK., Paszkowski M; Third Chair and Department of Gynecology, Medical University of Lublin, Lublin, Poland., Petraglia F; Obstetrics and Gynecology Unit, Department of Clinical Experimental and Biomedical Sciences, University of Florence, Florence, Italy., Renner SP; Department of Gynecology and Obstetrics, Hospital Böblingen, Klinikverbund-Suedwest, Sindelfingen 71065, Germany., Patel A; Department of Medical Affairs, Theramex UK Ltd, London, UK., Boolell M; Department of Medical Affairs, Theramex UK Ltd, London, UK., Bestel E; Department of Medical Affairs, Theramex UK Ltd, London, UK., Dolmans MM; Gynecology Research Laboratory, Institut de Recherche Expérimentale et Clinique, Department of Gynecology, Université Catholique de Louvain, Brussels, Belgium.; Gynecology Department, Cliniques Universitaires St-Luc, Brussels, Belgium. |
| المصدر: | Human reproduction (Oxford, England) [Hum Reprod] 2024 Jun 03; Vol. 39 (6), pp. 1208-1221. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 8701199 Publication Model: Print Cited Medium: Internet ISSN: 1460-2350 (Electronic) Linking ISSN: 02681161 NLM ISO Abbreviation: Hum Reprod Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford, UK : Oxford University Press Original Publication: Oxford ; Washington, DC : Published for the European Society of Human Reproduction and Embryology by IRL Press, [c1986- |
| مواضيع طبية MeSH: | Endometriosis*/drug therapy , Endometriosis*/complications , Dysmenorrhea*/drug therapy , Pelvic Pain*/drug therapy , Pelvic Pain*/etiology , Estradiol*/blood , Norethindrone*/administration & dosage , Norethindrone*/therapeutic use , Norethindrone*/analogs & derivatives , Norethindrone Acetate*, Humans ; Female ; Double-Blind Method ; Adult ; Prospective Studies ; Treatment Outcome ; Drug Therapy, Combination |
| مستخلص: | Study Question: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demonstrate better efficacy than placebo in the management of endometriosis-related dysmenorrhea and non-menstrual pelvic pain? Summary Answer: Combining 200 mg linzagolix with ABT was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain at 3 months of therapy, while a daily dose of 75 mg linzagolix yielded a significant decrease only in dysmenorrhea at 3 months. What Is Known Already?: A previously published Phase 2, dose-finding study reported that at a dose of 200 mg daily, linzagolix promotes full suppression of estradiol secretion to serum levels below 20 pg/ml and noted that the addition of ABT may be needed to manage hypoestrogenic side effects. At lower doses (75 mg and 100 mg/day), linzagolix maintains estradiol values within the target range of 20-60 pg/ml, which could be ideal to alleviate symptoms linked to endometriosis. Study Design, Size, Duration: EDELWEISS 3 was a multicenter, prospective, randomized, placebo-controlled, double-blind, double-dummy Phase 3 study to evaluate the safety and efficacy of linzagolix for the treatment of moderate-to-severe endometriosis-associated pain. Treatment was administered orally once daily for up to 6 months. Participants/materials, Setting, Methods: In the EDELWEISS 3 trial, 486 subjects with moderate-to-severe endometriosis-associated pain were randomized at a 1:1:1 ratio to one of the three study groups: placebo, 75 mg linzagolix alone or 200 mg linzagolix in association with ABT. Pain was measured daily on a verbal rating scale and recorded in an electronic diary. Main Results and the Role of Chance: At 3 months, the daily 200 mg linzagolix dose with ABT met the primary efficacy objective, showing clinically meaningful and statistically significant reductions in dysmenorrhea and non-menstrual pelvic pain, with stable or decreased use of analgesics. The proportion of responders for dysmenorrhea in the 200 mg linzagolix with ABT group was 72.9% compared with 23.5% in the placebo group (P < 0.001), while the rates of responders for non-menstrual pelvic pain were 47.3% and 30.9% (P = 0.007), respectively. The 75 mg linzagolix daily dose demonstrated a clinically meaningful and statistically significant reduction in dysmenorrhea versus placebo at 3 months. The proportion of responders for dysmenorrhea in the 75 mg linzagolix group was 44.0% compared with 23.5% in the placebo group (P < 0.001). Although the 75 mg dose showed a trend toward reduction in non-menstrual pelvic pain at 3 months relative to the placebo, it was not statistically significant (P = 0.279). Significant improvements in dyschezia and overall pelvic pain were observed in both linzagolix groups when compared to placebo. Small improvements in dyspareunia scores were observed in both linzagolix groups but they were not significant. In both groups, hypoestrogenic effects were mild, with low rates of hot flushes and bone density loss of <1%. A daily dose of 200 mg linzagolix with ABT or 75 mg linzagolix alone was found to significantly reduce dysmenorrhea and non-menstrual pelvic pain also at 6 months of therapy. Limitations, Reasons for Caution: Efficacy was compared between linzagolix groups and placebo; however, it would be useful to have results from comparative studies with estro-progestogens or progestogens. It will be important to ascertain whether gonadotropin-releasing hormone antagonists have significant benefits over traditional first-line medications. Wider Implications of the Findings: Linzagolix administered orally once daily at a dose of 200 mg in combination with add-back therapy (ABT) demonstrated better efficacy and safety than placebo in the management of moderate-to-severe endometriosis-associated pain. The quality of life was improved and the risks of bone loss and vasomotor symptoms were minimized due to the ABT. The 75 mg dose alone could be suitable for chronic treatment of endometriosis-associated pain without the need for concomitant hormonal ABT, but further research is needed to confirm this. If confirmed, it would offer a viable option for women who do not want to wish to have ABT or for whom it is contraindicated. Study Funding/competing Interest(s): Funding for the EDELWEISS 3 study was provided by ObsEva (Geneva, Switzerland). Analysis of data and manuscript writing were partially supported by ObsEva (Geneva, Switzerland), Theramex (London, UK) and Kissei (Japan) and grant 5/4/150/5 was awarded to M.-M.D. by FNRS. J.D. was a member of the scientific advisory board of ObsEva until August 2022, a member of the scientific advisory board of PregLem, and received personal fees from Gedeon Richter, ObsEva and Theramex. J.D. received consulting fees, speakers' fees, and travel support from Gedeon Richter, Obseva and Theramex, which was paid to their institution. C.B. has received fees from Theramex, Gedeon Richter, and Myovant, and travel support from Gedeon Richter-all funds went to the University of Oxford. He was a member of the data monitoring board supervising the current study, and served at an advisory board for endometriosis studies of Myovant. H.T. has received grants from Abbvie and was past president of ASRM. F.C.H. has received fees from Gedeon Richter and Theramex. O.D. received fees for lectures from Gedeon Richter and ObsEva and research grants for clinical studies from Preglem and ObsEva independent from the current study. A.H. has received grants from NIHR, UKRI, CSO, Wellbeing of Women, and Roche Diagnostics; he has received fees from Theramex. A.H.'s institution has received honoraria for consultancy from Roche Diagnostics, Gesynta, and Joii. M.P. has nothing to declare. F.P. has received fees from Theramex. S.P.R. has been a member of the scientific advisory board of Gedeon Richter and received fees from Gedeon Richter. A.P. and M.B. are employees of Theramex. E.B. was an employee of ObsEva, sponsor chair of the data monitoring board supervising the current study, and has been working as a consultant for Theramex since December 2022; she owns stock options in ObsEva. M.-M.D. has received fees and travel support from Gedeon Richter and Theramex. Trial Registration Number: NCT03992846. Trial Registration Date: 20 June 2019. Date of First Patient’s Enrollment: 13 June 2019. (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.) |
| References: | Hum Reprod. 2019 Feb 1;34(2):193-199. (PMID: 30551159) Fertil Steril. 2016 Dec;106(7):1552-1571.e2. (PMID: 27817837) Adv Ther. 2018 Mar;35(3):408-423. (PMID: 29450864) Hum Reprod Update. 2016 Nov;22(6):762-774. (PMID: 27591248) Rev Endocr Metab Disord. 2022 Jun;23(3):333-355. (PMID: 34405378) N Engl J Med. 2020 Mar 26;382(13):1244-1256. (PMID: 32212520) Fertil Steril. 2006 Dec;86(6):1561-72. (PMID: 17056043) Hum Reprod. 2012 May;27(5):1292-9. (PMID: 22422778) J Clin Endocrinol Metab. 2018 Dec 1;103(12):4561-4568. (PMID: 30357380) Int J Mol Sci. 2022 Jan 28;23(3):. (PMID: 35163463) Front Biosci (Elite Ed). 2012 Jan 01;4(1):23-40. (PMID: 22201853) Hum Reprod. 2021 Aug 18;36(9):2624-2625. (PMID: 34160579) Lancet. 2022 Sep 17;400(10356):896-907. (PMID: 36116480) Am J Obstet Gynecol. 1981 Mar 15;139(6):645-54. (PMID: 6452062) Drug Des Devel Ther. 2023 Feb 08;17:369-380. (PMID: 36789095) Womens Health (Lond). 2015 Aug;11(5):693-9. (PMID: 26439119) Lancet. 2004 Nov 13-19;364(9447):1789-99. (PMID: 15541453) Front Endocrinol (Lausanne). 2022 Oct 26;13:1020827. (PMID: 36387918) Fertil Steril. 2017 Mar;107(3):533-536. (PMID: 28162779) Fertil Steril. 1997 Oct;68(4):585-96. (PMID: 9341595) Fertil Steril. 2023 May;119(5):746-750. (PMID: 36925057) Reprod Sci. 2020 Apr;27(4):988-995. (PMID: 32100275) Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:68-91. (PMID: 29530425) Hum Reprod Open. 2022 Feb 26;2022(2):hoac009. (PMID: 35350465) Fertil Steril. 2014 Apr;101(4):927-35. (PMID: 24630080) Reprod Biomed Online. 2021 Feb;42(2):451-456. (PMID: 33277193) Fertil Steril. 2017 May;107(5):1181-1190.e2. (PMID: 28476181) BMJ. 2022 Nov 14;379:e070750. (PMID: 36375827) Hum Reprod Update. 2020 Jun 18;26(4):565-585. (PMID: 32412587) Hum Reprod. 2016 Apr;31(4):712-22. (PMID: 26851604) Hum Reprod Update. 2002 Jan-Feb;8(1):89-94. (PMID: 11866245) Am J Obstet Gynecol. 1992 Feb;166(2):740-5. (PMID: 1536260) Semin Reprod Med. 2017 Jan;35(1):88-97. (PMID: 28049214) J Clin Med. 2021 Mar 05;10(5):. (PMID: 33807739) N Engl J Med. 2017 Jul 6;377(1):28-40. (PMID: 28525302) Br J Clin Pharmacol. 2022 May;88(5):2359-2371. (PMID: 34904270) Obstet Gynecol. 2018 Jul;132(1):147-160. (PMID: 29889764) Front Glob Womens Health. 2021 Sep 27;2:729601. (PMID: 34816243) Lancet. 2022 Jun 18;399(10343):2267-2279. (PMID: 35717987) Lancet. 2021 Feb 27;397(10276):839-852. (PMID: 33640070) Endocr Rev. 2019 Aug 1;40(4):1048-1079. (PMID: 30994890) Int J Mol Sci. 2021 Oct 20;22(21):. (PMID: 34768770) J Clin Endocrinol Metab. 2017 May 1;102(5):1683-1691. (PMID: 28323948) Int J Mol Sci. 2021 Jul 01;22(13):. (PMID: 34281188) Fertil Steril. 2017 Mar;107(3):568-570. (PMID: 28259257) Hum Reprod. 2014 Mar;29(3):400-12. (PMID: 24435778) N Engl J Med. 2008 Sep 11;359(11):1136-42. (PMID: 18784103) Best Pract Res Clin Obstet Gynaecol. 2018 Jul;50:50-60. (PMID: 29576469) Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1082-1093. (PMID: 35690889) Fertil Steril. 2020 Jul;114(1):44-55. (PMID: 32505383) Hum Reprod Update. 2019 Jul 1;25(4):473-485. (PMID: 30809650) Fertil Steril. 2018 Jun;109(6):1086-1096. (PMID: 29871796) |
| معلومات مُعتمدة: | 5/4/150/5 ObsEva; Theramex; Kissei; NIHR; Gedeon Richter and Theramex |
| فهرسة مساهمة: | Keywords: dysmenorrhea; endometriosis; endometriosis-associated pain; linzagolix; non-menstrual pelvic pain; oral GnRH antagonist |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03992846 |
| المشرفين على المادة: | 4TI98Z838E (Estradiol) T18F433X4S (Norethindrone) 9S44LIC7OJ (Norethindrone Acetate) |
| تواريخ الأحداث: | Date Created: 20240422 Date Completed: 20240603 Latest Revision: 20240815 |
| رمز التحديث: | 20240815 |
| مُعرف محوري في PubMed: | PMC11144970 |
| DOI: | 10.1093/humrep/deae076 |
| PMID: | 38648863 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2350 |
|---|---|
| DOI: | 10.1093/humrep/deae076 |